Pediatrics · LP-006
Ibuprofen Oral suspension
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-006Pediatrics
- Generic identity
- IbuprofenOral suspension
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-006
- Generic identity
- Ibuprofen
- Presentation
- Oral suspension
- Catalogue strength
- 100 mg/5 mL
- Catalogue pack
- Bottle 60 mL / 100 mL
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: ibuprofen.
- Dosage form: oral suspension.
- Catalogue concentration: 100 mg/5 mL.
- Catalogue pack options: bottle 60 mL and bottle 100 mL.
- Catalogue category: Pediatrics; category is not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Approved age/weight range, indication and dose schedule.
- Suspension excipients, shaking instructions and measuring-device specification.
- Warnings/contraindications for the exact product and jurisdiction.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 100 mg/5 mL | Oral suspension | — | Bottle 60 mL | Pack option is explicit; age/weight eligibility and formulation instructions are held. |
| B | 100 mg/5 mL | Oral suspension | — | Bottle 100 mL | Pack option is explicit; age/weight eligibility and formulation instructions are held. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Ibuprofen is a non-steroidal anti-inflammatory drug used for pain, inflammation and fever in appropriate patients. Its benefits and risks differ from those of paracetamol. An oral suspension provides a measured liquid presentation, but concentration, age eligibility and the patient’s hydration status remain essential considerations. This educational information is not approved labeling for a Luang Pharma product and does not establish suitability for an infant or child.
Clinical context and therapeutic role
Clinical assessment should focus on the cause of pain or fever, the need for an anti-inflammatory medicine and the shortest appropriate period of symptom treatment. A child with persistent fever, severe pain, breathing difficulty or poor fluid intake may need examination. Kidney disease, asthma, previous reactions to other anti-inflammatory medicines and concurrent treatment influence selection. Pediatric use must follow the exact local product information and a suitable administration device.
Selected safety context
Important risks include gastrointestinal ulceration or bleeding, kidney injury and allergic reactions. Dehydration can increase kidney risk, particularly with vomiting or diarrhoea. Ibuprofen can trigger wheezing in susceptible patients and is generally avoided in children with chickenpox unless specifically advised. Do not duplicate other NSAIDs. Black stools, vomiting blood, severe abdominal pain, reduced urine or breathing difficulty require urgent assessment. Concentration errors and household teaspoons can lead to accidental overdose.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue identifies an oral suspension. A measured volume is meaningful only with the verified concentration and correct mixing instructions. The suspension vehicle, excipients and product-specific behavior cannot be inferred from the ingredient name, and different concentrations must not be compared using volume alone.
Follow the approved instructions for shaking and use a suitable calibrated oral device. Keep the bottle properly closed and labeled. Storage conditions and the permitted period after opening must be established from the actual supplied product; this profile does not assign either.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A pediatric clinician or pharmacist should confirm the diagnosis, authorized age range, weight-related assessment where relevant, concentration and measuring device. Catalogue placement in a pediatric category is not evidence of approval for children.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Approved label/leaflet with age/weight and administration instructions.
Finished-product specification and suspension formula.
Measuring-device and container/closure specification.
Registration/market-status evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: Ibuprofen for childrenArchived source classification: public-health medicine reference | Source revision recorded: Page reviewed 21 August 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-006.
Professional enquiries
Request product-specific evidence for LP-006.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.